Inno-206
Primary Mediastinal Large B Cell Lymphoma
University of WashingtonPhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 62/ 100
- Competitive Position
- 89/ 100
Competitive context
86 Active assets in the Primary Mediastinal Large B Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ifosfamide David Bond, MD | Phase 4 | BBB |
Inno-206 Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 4 | BBB |
ETOPOSIDE University of Washington | Phase 4 | BBB |
ETOPOSIDE University of Washington | Phase 4 | BBB |
(+)-VINCRISTINE Sun Yat-sen University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Inno-206 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →